Detalles de la búsqueda
1.
Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study.
BMC Cancer
; 24(1): 421, 2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38580937
2.
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
Cancer Immunol Immunother
; 72(1): 91-99, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35729418
3.
Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study.
Cancer Immunol Immunother
; 70(7): 2023-2033, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33423089
4.
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
Future Oncol
; 17(23): 3007-3016, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34156285
5.
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.
Eur Respir J
; 52(4)2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30262574
6.
Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
BMC Cancer
; 16: 210, 2016 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-26968843
7.
Uncommon MET mutational landscape in a non-small cell lung cancer patient treated with crizotinib: Case report.
Heliyon
; 10(11): e31944, 2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38845935
8.
Case Report: Coronaro-bronchial fistula vascularizing a squamous cell lung cancer.
Front Cardiovasc Med
; 10: 1279611, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38028494
9.
Incidence of venous thromboembolism and association with PD-L1 expression in advanced non-small cell lung cancer patients treated with first-line chemo-immunotherapy.
Front Oncol
; 13: 1221106, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38260845
10.
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.
J Cancer Res Clin Oncol
; 149(16): 15095-15102, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37626173
11.
Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax study.
Cancer Med
; 12(3): 2658-2665, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36000584
12.
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.
Target Oncol
; 18(4): 585-591, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37310660
13.
Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29).
Transl Lung Cancer Res
; 12(2): 266-276, 2023 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36895931
14.
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Target Oncol
; 18(6): 905-914, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37966566
15.
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
J Immunother
; 2023 Oct 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37807621
16.
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.
Ther Adv Med Oncol
; 14: 17588359221099399, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35694190
17.
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Cancers (Basel)
; 14(7)2022 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35406523
18.
Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.
Lung Cancer
; 174: 45-49, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36323057
19.
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Eur J Cancer
; 166: 51-59, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35278825
20.
Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report.
Thorac Cancer
; 12(8): 1240-1243, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33624409